The patent cliff has been good for generic-drugs companies this year, with over 40 brand-name...
Tuesday, December 4, 2012, 10:11 AM ETThe patent cliff has been good for generic-drugs companies this year, with over 40 brand-name treatments with $35B of annual sales losing their IP protection. However, the sector faces its own patent cliff over the next couple of years, due to fewer drugs losing that protection. In response, the generic companies are specializing in treatments that are hard to make, selling their own branded medicines, or making big acquisitions.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles